An oral retatrutide formulation has not been announced
The GLP-1R/GIPR/GcgR triple-agonist retatrutide achieves body weight loss (~25%) in just two-thirds of the time, potentially surpassing the efficacy of Roux-en-Y gastric bypass [29]
CKD and HF commonly coexist and exacerbate each other, as CKD increases the risk of HF, while HF accelerates kidney function decline [17]
However, differences in sociodemographic profile and comorbidities were present, such as higher incomes and educational level of GLP-1 RAs users compared with SGLT-2 inhibitor users and DPP-4 inhibitor users suggesting selection bias in prescription
"Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder"
Trulicity (dulaglutide) Approved - A weekly GLP-1 receptor agonist for managing type 2 diabetes that also supports moderate weight loss by regulating appetite and blood sugar